Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Incyte logo — Pharmaceutical Research | Oncology Product Development | Inc...

Incyte

Pharmaceutical Research | Oncology Product Development | Incyte.com

Founded 1991 United States Wilmington, United States 3425 employees IPO Total: $44.30M

General Information

Company Name Incyte
Founded Year 1991
Location United States Wilmington, United States
Employees 3425
Funding Stage IPO
Business Model B2B, B2C, B2D
Revenue Model Product Sales, Licensing
Social

BounceWatch is an independent company data service, not affiliated with Incyte. To contact Incyte, visit incyte.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Incyte compare?

A PDF of Incyte and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Incyte soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Incyte

Incyte, founded in 1991, is a global leader in the biopharmaceutical landscape, known for its commitment to resolving unmet medical needs through innovative drug discovery and development in the fields of oncology and inflammation & autoimmunity. With its headquarters in Wilmington, Delaware, the company operates with a workforce exceeding 2,600 across North America, Europe, and Asia.

Endowed with specialized expertise in medicinal chemistry and biology, Incyte boasts a robust portfolio of first-in-class medicines and a diversified pipeline of therapies. Importantly, the majority of these clinical candidates are the product of internal innovation. The company has been recognized by Science magazine and Newsweek for its strong workplace culture and impact.

Their latest funding, a $44.30M Post IPO Equity investment from Scuti Capital Management in March 2023, underscores confidence in their ongoing potential. Given their profound impact and strategic focus, Incyte remains an attractive prospect for investors seeking substantial contributions to healthcare advancements.

Business keywords: Pharmaceutical Research, Oncology Product Development, Biopharmaceutical Company, Innovative Medicines, Clinical Candidates, Medicinal Chemistry, Inflammation & Autoimmunity, Dermatology, First-in-Class Medicines, Oncology, Targeted Therapy, Immuno-oncology, Immunology, Healthcare Advances, Pipeline Development

Services & Products

Development of innovative medicines
Research and development in Hematology and Oncology
Treatment for Inflammation and Autoimmunity
Clinical program management
Partnership development

Target Customers

Patients Healthcare professionals Medical institutions

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity $44.30M 1
Scuti Capital Management
01 Mar 2023
IPO Undisclosed -
01 Nov 1993

Incyte Alternatives & Competitors

View All Alternatives
Incyte vs
Novartis
Novartis Switzerland

Reimagining medicine by transforming cancer

IPO
86998 employees
Biotechnology, Pharmaceutical
Incyte vs
Regor Therapeutics Group
Regor Therapeutics Group China

We aspire to be a world class innovative drug discovery company from China.

35 employees
Biotechnology, Pharmaceutical
Incyte vs
Laboratorios Biopas
Laboratorios Biopas Colombia

Una compañía centrada en el paciente latinoamericano.

Private Equity
529 employees
Pharmaceutical
View all alternatives

FAQ About Incyte

Pharmaceutical Research | Oncology Product Development | Incyte.com
Incyte was founded in 1991.
Incyte is headquartered in Wilmington, United States.
Incyte has a B2B, B2C and B2D business model. Its revenue comes from Product Sales and Licensing.
Incyte has approximately 3425 employees.
Incyte has completed 2 funding rounds, raising a total of $44.30M. The latest funding stage is IPO.
Incyte offers: Development of innovative medicines, Research and development in Hematology and Oncology, Treatment for Inflammation and Autoimmunity, Clinical program management, Partnership development.
Top alternatives and competitors to Incyte include Novartis, Regor Therapeutics Group, Laboratorios Biopas, Pheon Therapeutics, Dunad Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Incyte and Novartis are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Incyte, https://bouncewatch.com/company/incyte, updated 9 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout